Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 7Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Multiple Myeloma 4Lymphoma 4Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Hereditary Sensory and Autonomic Neuropathies 2Hematologic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1

Interventions

enzalutamide 7Abiraterone Acetate 4abiraterone 3Prednisone 3Docetaxel 3sapanisertib 1relugolix 1pembrolizumab 1onvansertib 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1apalutamide 1abemaciclib 1Prednisolone 1PF06821497 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-Resistant Prostate Cancer × sapanisertib × Clear all
NCT02091531 2019-11-21

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
9 enrolled 10 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡